Therapeutic efficacy of cyclin-dependent kinase inhibition in combination with ionizing radiation for lung cancer

References

• Appleyard MVC, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. 2009. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer. 124(2):465–472.
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Shailubhai K, Bahleda R, Gazzah A, Varga A, Hollebecque A, Massard C, Spreafico A, Reni M, Soria JC. 2017. Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors. Cancer Chemother Pharmacol. 79(6):1257–1265.
   PubMed Web of Science ®Google Scholar
• Baschnagel AM, Elnaggar JH, VanBeek HJ, Kromke AC, Skiba JH, Kaushik S, Abel L, Clark PA, Longhurst CA, Nickel KP, et al. 2021. ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient-derived xenografts. Mol Cancer Ther. 20(11):2129–2139.
   PubMed Web of Science ®Google Scholar
• Bliss CI. 1939. The toxicity of poisons applied jointly 1. Ann Appl Biol. 26(3):585–615.
   Google Scholar
• Chen JLY, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL, Kuo SH, Shieh MJ. 2021. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother. 70(2):391–404.
   PubMed Web of Science ®Google Scholar
• Chen JLY, Pan CK, Lin YL, Tsai CY, Huang YS, Yang WC, Hsu FM, Kuo SH, Shieh MJ. 2021. Preclinical evaluation of pegylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer. Strahlenther Onkol. 197(12):1131–1142.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, et al. 2019. SWOG S1400C (NCT02154490)—a phase II study of palbociclib for previously treated cell cycle gene alteration–positive patients with stage IV squamous cell lung cancer (Lung-MAP Substudy). J Thorac Oncol. 14(10):1853–1859.
   PubMed Web of Science ®Google Scholar
• Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, et al. 2010. Targeting the cyclin E-CDK-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res. 16(1):109–120.
   PubMed Web of Science ®Google Scholar
• Gary C, Hajek M, Biktasova A, Bellinger G, Yarbrough WG, Issaeva N. 2016. Selective antitumor activity of roscovitine in head and neck cancer. Oncotarget. 7(25):38598–38611.
   PubMedGoogle Scholar
• Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, et al. 2015. CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110. Cancer Res. 75(10):2029–2038.
   PubMed Web of Science ®Google Scholar
• Huang YS, Chen JL, Chen JY, Lee YF, Huang JY, Kuo SH, Yen RF, Chang YC. 2019. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. Strahlenther Onkol. 195(8):707–718.
   PubMed Web of Science ®Google Scholar
• Huang YS, Chen JL, Hsu FM, Huang JY, Ko WC, Chen YC, Jaw FS, Yen RF, Chang YC. 2018. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients. J Magn Reson Imaging. 47(1):191–199.
   PubMed Web of Science ®Google Scholar
• Hui ABY, Yue S, Shi W, Alajez NM, Ito E, Green SR, Frame S, O'Sullivan B, Liu F-F. 2009. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res. 15(11):3716–3724.
   PubMed Web of Science ®Google Scholar
• Kodym E, Kodym R, Reis AE, Habib AA, Story MD, Saha D. 2009. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer. 66(1):37–47.
   PubMed Web of Science ®Google Scholar
• Lanevski A, Giri AK, Aittokallio T. 2020. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 48(W1):W488–W493.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, et al. 2010. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 46(18):3243–3250.
   PubMed Web of Science ®Google Scholar
• Lu W, Chen L, Peng Y, Chen J. 2001. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene. 20(25):3206–3216.
   PubMed Web of Science ®Google Scholar
• MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, Lane DP, Green SR. 2005. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65(12):5399–5407.
   PubMed Web of Science ®Google Scholar
• Marti TM, Hefner E, Feeney L, Natale V, Cleaver JE. 2006. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA double-strand breaks. Proc Natl Acad Sci USA. 103(26):9891–9896.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Yasufuku K, Hiroshima K, Nakajima T, Yoshida S, Suzuki M, Sekine Y, Shibuya K, Iizasa T, Farouk A, et al. 2007. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 non-small cell lung cancer. Cancer. 109(12):2506–2514.
   PubMed Web of Science ®Google Scholar
• Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, Cook JA, Mitchell JB. 2018. Abemaciclib, a selective CDK4/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer in vitro and in vivo. Clin Cancer Res. 24(16):3994–4005.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, et al. 2016. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6(7):740–753.
   PubMed Web of Science ®Google Scholar
• Qin A, Reddy HG, Weinberg FD, Kalemkerian GP. 2020. Cyclin-dependent kinase inhibitors for the treatment of lung cancer. Expert Opin Pharmacother. 21(8):941–952.
   PubMed Web of Science ®Google Scholar
• Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, Bristow RG, Saha D. 2012. AZD5438, an inhibitor of CDK1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys. 84(4):e507–e514.
   PubMed Web of Science ®Google Scholar
• Sak A, Stueben G, Groneberg M, Böcker W, Stuschke M. 2005. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br J Cancer. 92(6):1089–1097.
   PubMed Web of Science ®Google Scholar
• Santo L, Siu KT, Raje N. 2015. Targeting cyclin-dependent kinases and cell cycle progression in human cancers. Semin Oncol. 42(6):788–800.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. 2021. Cancer statistics, 2021. CA A Cancer J Clin. 71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Sterlacci W, Fiegl M, Tzankov A. 2012. Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer. Pathobiology. 79(4):175–194.
   PubMed Web of Science ®Google Scholar
• van Bijsterveldt L, Durley SC, Maughan TS, Humphrey TC. 2021. The challenge of combining chemo- and radiotherapy with checkpoint kinase inhibitors. Clin Cancer Res. 27(4):937–962.
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Walton MI, Garrett MD, Workman P. 2004. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64(1):262–272.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang T, Gu ZP, Zhou YA, Han Y, Li XF, Wang XP, Cheng QS, Mei QB. 2008. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J Radiat Res. 49(5):541–548.
   PubMed Web of Science ®Google Scholar